GlaxoSmithKline has reached a $49 million settlement agreement with a class of direct purchasers who accused the drug maker of bringing "sham" patent litigation against manufacturers of generic versions of its popular antidepressant Wellbutrin SR.
October 19, 2011 at 12:00 AM
1 minute read
The original version of this story was published on The Legal Intelligencer
GlaxoSmithKline has reached a $49 million settlement agreement with a class of direct purchasers who accused the drug maker of bringing “sham” patent litigation against manufacturers of generic versions of its popular antidepressant Wellbutrin SR in an attempt to prolong its monopoly on the market.
The plaintiffs filed a motion for final approval of the settlement on Friday, about four-and-a-half months after the parties reached an agreement during mediation.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
